Adverse Drug Reactions Associated with Ceftaroline Use: A 2-Center Retrospective Cohort

Journal of Allergy and Clinical Immunology: In Practice

Volumn 4, Issue 4, 2016, Pages 740-746

  Blumenthal, Kimberly G ^a,b   Kuhlen, James L ^c   Weil, Ana A ^a,b   Varughese, Christy A ^d   Kubiak, David W ^e   Banerji, Aleena ^a,b   Shenoy, Erica S ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE GREENVILLE   (United States)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Adverse drug reaction; allergy; beta lactam; Ceftaroline; Drug; Hypersensitivity

Indexed keywords

AZITHROMYCIN; CEFACLOR; CEFALEXIN; CEFAZOLIN; CEFEPIME; CEFTAROLINE; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN; CIPROFLOXACIN; CLINDAMYCIN; COLISTIN; COTRIMOXAZOLE; DAPTOMYCIN; DOXYCYCLINE; FLUCONAZOLE; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MEROPENEM; METRONIDAZOLE; MICAFUNGIN; MOXIFLOXACIN; NAFCILLIN; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; RIFAMPICIN; TOBRAMYCIN; VANCOMYCIN; ANTIINFECTIVE AGENT; CEPHALOSPORIN DERIVATIVE;

ABDOMINAL INFECTION; ACUTE KIDNEY FAILURE; ADULT; ANAPHYLAXIS; ARTICLE; ATOPY; BACTEREMIA; BONE INFECTION; CHRONIC KIDNEY FAILURE; CLOSTRIDIUM DIFFICILE INFECTION; COHORT ANALYSIS; COMMUNITY ACQUIRED PNEUMONIA; DIABETES MELLITUS; DISEASE COURSE; DRUG HYPERSENSITIVITY; DRUG USE; EMPYEMA; ENDOCARDITIS; EOSINOPHILIA; EPIDURAL ABSCESS; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; GENERAL HOSPITAL; GRAFT INFECTION; HEMATOLOGIC DISEASE; HEPATITIS; HUMAN; HYPERSENSITIVITY; HYPERTENSION; HYPERTRANSAMINASEMIA; INTRAVENOUS DRUG ABUSE; LEUKOCYSTOCLASTIC VASCULITIS; LEUKOPENIA; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MIDDLE AGED; MULTICENTER STUDY; NEUTROPENIA; ORAL MUCOSAL DISEASE; PERIPHERAL VASCULAR DISEASE; PNEUMONIA; PRURITUS; RACE; RASH; RETROSPECTIVE STUDY; RISK FACTOR; SIDE EFFECT; SKIN EXFOLIATION; SWELLING; THROMBOCYTOPENIA; TONGUE SWELLING; URTICARIA; VASCULAR DISEASE; VASCULITIS; AGED; CASE REPORT; CLINICAL TRIAL; MALE;

ADULT; AGED; ANTI-BACTERIAL AGENTS; CEPHALOSPORINS; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84964587141     PISSN: 22132198     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaip.2016.03.008     Document Type: Article

References (29)

1. Duplessis, C., Crum-Cianflone, N., Ceftaroline: a new cephalosporin with activity against methicillin-resistant Staphylococcus aureus (MRSA). Clin Med Rev Ther, 2011, 3.
2. File, T.M., Wilcox, M.H., Stein, G.E., Summary of ceftaroline fosamil clinical trial studies and clinical safety. Clin Infect Dis 55 (2012), S173–S180.
3. Pasquale, T.R., Tan, M.J., Trienski, T.L., File, T.M. Jr., Methicillin-resistant Staphylococcus aureus nosocomial pneumonia patients treated with ceftaroline: retrospective case series of 10 patients. J Chemother 27 (2015), 29–34.
4. Teflaro [package insert], 2010, Forest Laboratories, New York, NY.
5. Stryjewski, M.E., Jones, R.N., Corey, G.R., Ceftaroline: clinical and microbiology experience with focus on methicillin-resistant Staphylococcus aureus after regulatory approval in the USA. Diagn Microbiol Infect Dis 81 (2014), 183–188.
6. Casapao, A.M., Davis, S.L., Barr, V.O., Klinker, K.P., Goff, D.A., Barber, K.E., et al. Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy. Antimicrob Agents Chemother 58 (2014), 2541–2546.
7. Thong, B.Y., Tan, T.C., Epidemiology and risk factors for drug allergy. Br J Clin Pharmacol 71 (2011), 684–700.
8. Kelly, W.N., Potential risks and prevention, part 1: fatal adverse drug events. Am J Health Syst Pharm 58 (2001), 1317–1324.
9. Kelkar, P.S., Li, J.T., Cephalosporin allergy. N Engl J Med 345 (2001), 804–809.
10. Macy, E., Contreras, R., Adverse reactions associated with oral and parenteral use of cephalosporins: a retrospective population-based analysis. J Allergy Clin Immunol 135 (2015), 745–752.
11. Weiss, M.E., Bernstein, D.I., Blessing-Moore, J., Cox, L., Lang, D.M., Nicklas, R.A., et al. Drug allergy: an updated practice parameter. Ann Allergy Asthma Immunol 105 (2010), 259–273.e78.
12. Corey, G.R., Wilcox, M.H., Talbot, G.H., Thye, D., Friedland, D., Baculik, T., CANVAS 1: the first phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 65 (2010), iv41–iv51.
13. Wilcox, M.H., Corey, G.R., Talbot, G.H., Thye, D., Friedland, D., Baculik, T., CANVAS 2: the second phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother 65 (2010), iv53–iv65.
14. File, T.M., Low, D.E., Eckburg, P.B., Talbot, G.H., Friedland, H.D., Lee, J., et al. FOCUS 1: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother 66 (2011), 491–498.
15. Low, D.E., File, T.M., Eckburg, P.B., Talbot, G.H., Friedland, D.H., Lee, J., et al. FOCUS 2: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother 66 (2011), iii33–iii44.
16. Griffiths, C.L., Gutierrez, K.C., Pitt, R.D., Lovell, R.D., Eosinophilic pneumonia induced by ceftaroline. Am J Health Syst Pharm 71 (2014), 403–406.
17. Rimawi, R.H., Frenkel, A., Cook, P.P., Ceftaroline–a cause for neutropenia. J Clin Pharm Ther 38 (2013), 330–332.
18. Sulaiman, K., Locati, J., Sidhu, I., Sangha, B., Allergic interstitial nephritis due to ceftaroline. Am J Med Sci 348 (2014), 354–355.
19. Yam, K.F., Kwan, K.B., A case of profound neutropenia and agranulocytosis associated with off-label use of ceftaroline. Am J Health-System Pharm 71 (2014), 1457–1461.
20. Jones, J.M., Richter, L.M., Alonto, A., Leedahl, D.D., Desensitization to ceftaroline in a patient with multiple medication hypersensitivity reactions. Am J Health Syst Pharm 72 (2015), 198–202.
21. Valour, F., Does prolonged ceftaroline therapy frequently cause neutropenia?. Med Mal Infect, 44, 2014, 488.
22. Jain, R., Chan, J.D., Rogers, L., Dellit, T.H., Lynch, J.B., Pottinger, P.S., High incidence of discontinuations due to adverse events in patients treated with ceftaroline. Pharmacotherapy 34 (2014), 758–763.
23. Blumenthal, K.G., Shenoy, E.S., Varughese, C.A., Hurwitz, S., Hooper, D.C., Banerji, A., Impact of a clinical guideline for prescribing antibiotics to inpatients reporting penicillin or cephalosporin allergy. Ann Allergy Asthma Immunol, 2015, 294–300.
24. Kuperman, G.J., Marston, E., Paterno, M., Rogala, J., Plaks, N., Hanson, C., et al. Creating an enterprise-wide allergy repository at Partners HealthCare System. AMIA Annu Symp Proc, 2003, 376–380.
25. Romano, A., Torres, M.J., Namour, F., Mayorga, C., Artesani, M.C., Venuti, A., et al. Immediate hypersensitivity to cephalosporins. Allergy 57 (2002), 52–57.
26. Macy, E., Ho, N., Multiple drug intolerance syndrome: prevalence, clinical characteristics, and management. Ann Allergy Asthma Immunol 108 (2012), 88–93.
27. An, M.M., Shen, H., Zhang, J.D., Xu, G.T., Jiang, Y.Y., Linezolid versus vancomycin for methicillin-resistant Staphylococcus aureus infection: a meta-analysis of randomised controlled trials. Int J Antimicrob Agents 41 (2013), 426–433.
28. Kuhlen, J.L., Blumenthal, K.G., Sokol, C.L., Balekian, D.S., Weil, A.A., Varughese, C.A., Shenoy, E.S., Ceftaroline desensitization procedure in a pregnant patient with multiple drug allergies. Open Forum Infect Dis, 2, 2015, ofv027.
29. Berry, L.L., Segal, R., Sherrin, T.P., Fudge, K.A., Sensitivity and specificity of three methods of detecting adverse drug reactions. Am J Hosp Pharm 45 (1988), 1534–1539.